TABLE 2.
The Akaike information criteria (AIC) and bayesian information criteria (BIC).
| Type of distribution | Tislelizumab plus chemotherapy (OS) | Placebo plus chemotherapy (OS) | Tislelizumab plus chemotherapy (PFS) | Placebo plus chemotherapy (PFS) | ||||
|---|---|---|---|---|---|---|---|---|
| AIC | BIC | AIC | BIC | AIC | BIC | AIC | BIC | |
| Exponential | 3,073.373 | 3,077.590 | 3,190.154 | 3,194.360 | 2,623.539 | 2,627.755 | 2,605.722 | 2,609.928 |
| Gamma | 3,059.935 | 3,068.368 | 3,142.067 | 3,150.480 | 2,623.622 | 2,632.055 | 2,592.746 | 2,601.159 |
| Generalized gamma | 3,053.079 | 3,065.729 | 3,132.048 | 3,144.667 | 2,539.585 | 2,552.235 | 2,521.854 | 2,534.473 |
| Gompertz | 3,075.256 | 3,083.689 | 3,185.289 | 3,193.702 | 2,583.947 | 2,592.380 | 2,594.866 | 2,603.279 |
| Weibull | 3,064.916 | 3,073.349 | 3,154.027 | 3,162.440 | 2,625.195 | 2,633.628 | 2,603.969 | 2,612.382 |
| WeibullPH' | 3,064.916 | 3,073.349 | 3,154.027 | 3,162.440 | 2,625.195 | 2,633.628 | 2,603.969 | 2,612.382 |
| Log-logistic | 3,040.735 | 3,049.168 | 3,119.800 | 3,128.213 | 2,527.995 | 2,536.428 | 2,519.063 | 2,527.476 |
| Lognormal | 3,065.127 | 3,073.560 | 3,136.923 | 3,145.33 | 2,541.685 | 2,550.118 | 2,523.609 | 2,532.022 |
OS: overall survival; PFS: progression-free survival.